Optimization and validation of the international metabolic prognostic index for CD19 CAR-T in large B-cell lymphoma

Abstract While CD19-directed CAR T-cell therapy represents a transformative immunotherapy for relapsed/refractory large B-cell lymphoma (r/r LBCL), more than 50% of patients ultimately progress or relapse. Recently, the International Metabolic Prognostic Index (IMPI) – incorporating age, stage, and...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Michael Winkelmann, Sandeep S. Raj, Michael D. Jain, Gloria Iacoboni, Fabian Müller, Leo Hansmann, Magdalena Corona, Alejandro Luna, Khushali Jhaveri, Gunjan L. Shah, Michael Scordo, Turab Mohammad, Erin A. Dean, Gabriel T. Sheikh, Wolfgang G. Kunz, Tobias Tix, Veit L. Bücklein, Akshay Bedmutha, Doris Leithner, Michael von Bergwelt-Baildon, Alexander P. Boardman, M. Lia Palomba, Jae H. Park, Gilles Salles, Miguel-Angel Perales, Heiko Schöder, Marion Subklewe, Pere Barba, Frederick L. Locke, Roni Shouval, Kai Rejeski
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Nature Publishing Group 2025-08-01
coleção:	Blood Cancer Journal
Acesso em linha:	https://doi.org/10.1038/s41408-025-01338-1
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!